Correction: Simultaneous expression of furin and vascular endothelial growth factor in human oral tongue squamous cell carcinoma progression (Clinical Cancer Research (2004) 10 (4480-4488) DOI: 10.1158/1078-0432.CCR-03-0670);Simultaneous expression of furin and vascular endothelial growth factor in human oral tongue squamous cell carcinoma progression

Clinical Cancer Research

Volumn 10, Issue 13, 2004, Pages 4480-4488

  López De Cicco, Ricardo ^a   Watson, James C ^a   Bassi, Daniel E ^a   Litwin, Samuel ^a   Klein Szanto, Andrés J ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FURIN; TUMOR MARKER; VASCULOTROPIN; VASCULOTROPIN C;

ANGIOGENESIS; ARTICLE; CANCER DIAGNOSIS; CANCER INVASION; CARCINOGENESIS; CELL DENSITY; CELL LINE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE COURSE; DYSPLASIA; GLOSSECTOMY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MICROVASCULATURE; PRECURSOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SQUAMOUS CELL CARCINOMA; TONGUE CARCINOMA; WESTERN BLOTTING;

EID: 3042852155     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-19-0490     Document Type: Erratum

References (69)

1. Canto MT, Devesa SS. Oral cavity and pharynx cancer incidence rates in the United States, 1975-1998. Oral Oncol 2002;38:610-7.
2. Foulds L, Neoplastic development. New York: Academic Press, 1969.
3. Portella G, Liddell J, Crombie R, et al. Molecular mechanisms of invasion and metastasis during mouse skin tumour progression. Invasion Metastasis 1994;14:7-16.
4. Portella G, Cumming SA, Liddell J, et al. Transforming growth factor beta is essential for spindle cell conversion of mouse skin carcinoma in vivo: implications for tumor invasion. Cell Growth Differ 1998;9:393-404.
5. Klein-Szanto AJ, Larcher F, Bonfil RD, Conti CJ. Multistage chemical carcinogenesis protocols produce spindle cell carcinomas of the mouse skin. Carcinogenesis (Lond) 1989;10:2169-72.
6. Gleich LL, Salamone FN. Molecular genetics of head and neck cancer. Cancer Control 2002;9:369-78.
7. Helliwell TR. Molecular markers of metastasis in squamous carcinomas. J Pathol 2001;194:289-93.
8. Forastiere A, Koch W, Trotti A, Sidransky D. Head and neck cancer. N Engl J Med 2001;345:1890-900.
9. Hosaka M, Nagahama M, Kim WS, et al. Arg-X-Lys/Arg-Arg motif as a signal for precursor cleavage catalyzed by furin within the constitutive secretory pathway. J Biol Chem 1991;266:12127-30.
10. Khatib AM, Siegfried G, Chretien M, Metrakos P, Seidah NG. Proprotein convertases in tumor progression and malignancy: novel targets in cancer therapy. Am J Pathol 2002;160:1921-35.
11. Pei D, Weiss SJ. Furin-dependent intracellular activation of the human stromelysin-3 zymogen. Nature (Lond) 1995;375:244-7.
12. Yana I, Weiss SJ. Regulation of membrane type-1 matrix metalloproteinase activation by proprotein convertases. Mol Biol Cell 2000;11: 2387-401.
13. Dubois CM, Blanchette F, Laprise MH, Leduc R, Grondin F, Seidah NG. Evidence that furin is an authentic transforming growth factor-beta1-converting enzyme. Am J Pathol 2001;158:305-16.
14. Duguay SJ, Jin Y, Stein J, Duguay AN, Gardner P, Steiner DF. Post-translational processing of the insulin-like growth factor-2 precursor. Analysis of O-glycosylation and endoproteolysis. J Biol Chem 1998;273:18443-51.
15. Lehmann M, Andre F, Bellan C, et al. Deficient processing and activity of type I insulin-like growth factor receptor in the furin-deficient LoVo-C5 cells. Endocrinology 1998;139:3763-71.
16. Seidah NG, Chretien M. Eukaryotic protein processing: endoproteolysis of precursor proteins. Curr Opin Biotechnol 1997;8:602-7.
17. Nakayama K. Furin: a mammalian subtilisin/Kex2p-like endoprotease involved in processing of a wide variety of precursor proteins. Biochem J 1997;327(Pt 3):625-35.
18. Zhou A, Webb G, Zhu X, Steiner DF. Proteolytic processing in the secretory pathway. J Biol Chem 1999;274:20745-8.
19. Seidah NG, Mowla SJ, Hamelin J, et al. Mammalian subtilisin/kexin isozyme SKI-1: a widely expressed proprotein convertase with a unique cleavage specificity and cellular localization. Proc Natl Acad Sci USA 1999;96:1321-6.
20. Molloy SS, Thomas L, VanSlyke JK, Stenberg PE, Thomas G. Intracellular trafficking and activation of the furin proprotein convertase: localization to the TGN and recycling from the cell surface. EMBO J 1994;13:18-33.
21. Schafer W, Stroh A, Berghofer S, et al. Two independent targeting signals in the cytoplasmic domain determine trans-Golgi network localization and endosomal trafficking of the proprotein convertase furin. EMBO J 1995;14:2424-35.
22. Shapiro J, Sciaky N, Lee J, Bosshart H, Angeletti RH, Bonifacino JS. Localization of endogenous furin in cultured cell lines. J Histochem Cytochem 1997;45:3-12.
23. Schalken JA, Roebroek AJ, Oomen PP, et al. fur gene expression as a discriminating marker for small cell and nonsmall cell lung carcinomas. J Clin Investig 1987;80:1545-9.
24. Mbikay M, Sirois F, Yao J, Seidah NG, Chretien M. Comparative analysis of expression of the proprotein convertases furin, PACE4, PC1 and PC2 in human lung tumours. Br J Cancer 1997;75:1509-14.
25. Cheng M, Watson PH, Paterson JA, Seidah N, Chretien M, Shiu RP. Pro-protein convertase gene expression in human breast cancer. Int J Cancer 1997;71:966-71.
26. Bassi DE, Mahloogi H, Al-Saleem L, Lopez De Cicco R, Ridge JA, Klein-Szanto AJ. Elevated furin expression in aggressive human head and neck tumors and tumor cell lines. Mol Carcinog 2001;31:224-32.
27. Jin L, Kulig E, Qian X, et al. Distribution and regulation of proconvertases PC1 and PC2 in human pituitary adenomas. Pituitary 1999;1:87-95.
28. Kajiwara H, Itoh Y, Itoh J, Yasuda M, Osamura RY. Immunohistochemical expressions of prohormone convertase (PC)1/3 and PC2 in carcinoids of various organs. Tokai J Exp Clin Med 1999;24:13-20.
29. Diaz-Flores L, Gutierrez R, Varela H. Angiogenesis: an update. Histol Histopathol 1994;9:807-43.
30. Folkman J. Angiogenesis-retrospect and outlook. EXS 1992;61: 4-13.
31. Folkman J. Proceedings: tumor angiogenesis factor. Cancer Res 1974;34:2109-13.
32. Folkman J, Merler E, Abernathy C, Williams G. Isolation of a tumor factor responsible or angiogenesis. J Exp Med 1971;133:275-88.
33. Brown LF, Detmar M, Claffey K, et al. Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. EXS 1997;79:233-69.
34. Ferrer FA, Miller LJ, Andrawis RI, et al. Vascular endothelial growth factor (VEGF) expression in human prostate cancer: in situ and in vitro expression of VEGF by human prostate cancer cells. J Urol 1997;157:2329-33.
35. Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 1995;55:3964-8.
36. Bancher-Todesca D, Obermair A, Bilgi S, et al. Angiogenesis in vulvar intraepithelial neoplasia. Gynecol Oncol 1997;64:496-500.
37. Abu-Jawdeh GM, Faix JD, Niloff J, Tet al. Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms. Lab Investig 1996;74:1105-15.
38. Brown LF, Berse B, Jackman RW, et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol 1995;26:86-91.
39. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995;146:1029-39.
40. Shpitzer T, Chaimoff M, Gal R, Stern Y, Feinmesser R, Segal K. Tumor angiogenesis as a prognostic factor in early oral tongue cancer. Arch Otolaryngol Head Neck Surg 1996;122:865-8.
41. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 1991;324:1-8.
42. Murray JD, Carlson GW, McLaughlin K, et al. Tumor angiogenesis as a prognostic factor in laryngeal cancer. Am J Surg 1997;174:523-6.
43. Sauter ER, Nesbit M, Watson JC, Klein-Szanto A, Litwin S, Herlyn M. Vascular endothelial growth factor is a marker of tumor invasion and metastasis in squamous cell carcinomas of the head and neck. Clin Cancer Res 1999;5:775-82.
44. Kishimoto K, Sasaki A, Yoshihama Y, Mese H, Tsukamoto G, Matsumura T. Expression of vascular endothelial growth factor-C predicts regional lymph node metastasis in early oral squamous cell carcinoma. Oral Oncol 2003;39:391-6.
45. Neuchrist C, Erovic BM, Handisurya A, et al. Vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 expression in squamous cell carcinomas of the head and neck. Head Neck 2003;25:464-74.
46. Huang HY, Ho CC, Huang PH, Hsu SM. Co-expression of VEGF-C and its receptors, VEGFR-2 and VEGFR-3, in endothelial cells of lymphangioma. Implication in autocrine or paracrine regulation of lymphangioma. Lab Investig 2001;81:1729-34.
47. Joukov V, Pajusola K, Kaipainen A, et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J 1996;15:290-8.
48. Karkkainen MJ, Makinen T, Alitalo K. Lymphatic endothelium: a new frontier of metastasis research. Nat Cell Biol 2002;4:E2-5.
49. Joukov V, Sorsa T, Kumar V, et al. Proteolytic processing regulates receptor specificity and activity of VEGF-C. EMBO J 1997;16:3898-911.
50. Siegfried G, Basak A, Cromlish JA, et al. The secretory proprotein convertases furin, PC5, and PC7 activate VEGF-C to induce tumorigenesis. J Clin Investig 2003;111:1723-32.
51. Caamano J, Zhang SY, Rosvold EA, Bauer B, Klein-Szanto AJ. p53 alterations in human squamous cell carcinomas and carcinoma cell lines. Am J Pathol 1993;142:1131-9.
52. Ishibashi H, Shiratuchi T, Nakagawa K, et al. Hypoxia-induced angiogenesis of cultured human salivary gland carcinoma cells enhances vascular endothelial growth factor production and basic fibroblast growth factor release. Oral Oncol 2001;37:77-83.
53. Bassi DE, Lopez De Cicco R, Mahloogi H, Zucker S, Thomas G, Klein-Szanto AJ. Furin inhibition results in absent or decreased invasiveness and tumorigenicity of human cancer cells. Proc Natl Acad Sci USA 2001;98:10326-31.
54. Bassi DE, Mahloogi H, Lopez De Cicco R, Klein-Szanto A. Increased furin activity enhances the malignant phenotype of human head and neck cancer cells. Am J Pathol 2003;162:439-47.
55. Mercapide J, Lopez De Cicco R, Bassi DE, Castresana JS, Thomas G, Klein-Szanto AJ. Inhibition of furin-mediated processing results in suppression of astrocytoma cell growth and invasiveness. Clin Cancer Res 2002;8:1740-6.
56. O-charoenrat P, Rhys-Evans P, Eccles SA. Expression of vascular endothelial growth factor family members in head and neck squamous cell carcinoma correlates with lymph node metastasis. Cancer (Phila) 2001;92:556-68.
57. Salven P, Lymboussaki A, Heikkila P, J et al. Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors. Am J Pathol 1998;153:103-8.
58. Kalnins IK, Leonard AG, Sako K, Razack MS, Shedd DP. Correlation between prognosis and degree of lymph node involvement in carcinoma of the oral cavity. Am J Surg 1977;134:450-4.
59. Ohta Y, Shridhar V, Bright RK, et al. VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours. Br J Cancer 1999;81:54-61.
60. Mandriota SJ, Jussila L, Jeltsch M, et al. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J 2001;20:672-82.
61. Beasley NJ, Prevo R, Banerji S, et al. Intratumoral lymphangiogenesis and lymph node metastasis in head and neck cancer. Cancer Res 2002;62:1315-20.
62. Sedivy R, Beck-Mannagetta J, Haverkampf C, Battistutti W, Honigschnabl S. Expression of vascular endothelial growth factor-C correlates with the lymphatic microvessel density and the nodal status in oral squamous cell cancer. J Oral Pathol Med 2003;32:455-60.
63. Ninck S, Reisser C, Dyckhoff G, Helmke B, Bauer H, Herold-Mende C. Expression profiles of angiogenic growth factors in squamous cell carcinomas of the head and neck. Int J Cancer 2003;106:34-44.
64. Siegfried G, Khatib AM, Benjannet S, Chretien M, Seidah NG. The proteolytic processing of pro-platelet-derived growth factor-A at RRKR(86) by members of the proprotein convertase family is functionally correlated to platelet-derived growth factor-A-induced functions and tumorigenicity. Cancer Res 2003;63:1458-63.
65. Arbeit JM. Transgenic models of epidermal neoplasia and multistage carcinogenesis. Cancer Surv 1996;26:7-34.
66. Folkman J, Watson K, Ingber D, Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature (Lond) 1989;339:58-61.
67. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-64.
68. Bolontrade MF, Stern MC, Binder RL, Zenklusen JC, Gimenez-Conti IB, Conti CJ. Angiogenesis is an early event in the development of hemically induced skin tumors. Carcinogenesis (Lond) 1998;19: 2107-13.
69. Watson JC, Cooper H, Babb J, Sigurdson ER, Klein-Szanto AJP. Angiogenesis is an early event in the adenoma-carcinoma sequence in human colon cancer. Surg Forum 1998;50:440-2.